Erratum for “A multicenter randomized controlled trial of medium‐chain triglyceride dietary supplementation on epilepsy in dogs”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiet and metabolism studies · Metabolism and Genetic Disorders · Pharmacological Effects and Toxicity Studies
Berk BA, Law TH, Packer RMA, et al. A multicenter randomized controlled trial of medium‐chain triglyceride dietary supplementation on epilepsy in dogs. J Vet Intern Med. 2020;34(3):1248‐1259. doi:10.1111/jvim.15756
The conflict of interest declaration was missing information about two authors. The missing information is shown below:
Andrea Tipold serves as Associate Editor for the Journal of Veterinary Internal Medicine. She was not involved in review of this manuscript.
Holger Volk in last 5 years served as contract researcher for: Nestle 2012‐2014 and 2017‐2020—dietary modification of epilepsy in dogs; Boehringer Ingelheim 2014‐2015—investigating the effects of imepitoin behavioral, physiologic and owner reported indicators of anxiety in dogs treated for idiopathic epilepsy; CASE BBSRC PhD studentship 2012‐2016—metabolic profiling of epilepsy in dogs; American Kennel Club American Health Foundation 2016‐2020—Investigating the Effect of a Ketogenic Medium Chain Triglycerides Supplement on the treatment of Canine Idiopathic Epilepsy and its behavioral comorbidities; BBSRC 2017‐2020—Investigating the relationship between epilepsy, drug‐resistance and affective disorders in the domestic dog BB/P001874/1; provided continuous education for veterinary surgeons sponsored by Nestle, Boehringer Ingelheim and Virbac in the last 5 years.
The authors did not allow any bias from any of these conflicts of interest to affect the design, analysis or writing of the paper.